Apoptosis is a highly regulated cellular process. Aberration in apoptosis is a common
characteristic of various disorders. Therefore, proteins involved in apoptosis are prime …

Members of the Bcl-2-protein family are key controllers of apoptotic cell death. The family is
divided into antiapoptotic (including Bcl-2 itself, Bcl-xL, Mcl-1, etc.) and proapoptotic …

Small-cell lung cancer (SCLC) is an aggressive malignancy with limited therapeutic options.
The dismal prognosis in SCLC is in part associated with an upregulation of BCL-2 family anti …

BCL-XL and BCL-2 are important targets for cancer treatment. BCL-XL specific proteolysis-
targeting chimeras (PROTACs) have been developed to circumvent the on-target platelet …

Introduction The anti-apoptotic BCL-2 family proteins, such as BCL-2, BCL-XL, and MCL-1,
are excellent cancer therapeutic targets. The FDA approval of BCL-2 selective inhibitor …

Anti-estrogens or aromatase inhibitors in combination with cyclin-dependent kinase 4 and 6
(CDK4/6) inhibitors are the current standard of care for estrogen receptor-positive (ER+) Her …

BCL-xL and BCL-2 are validated therapeutic targets in small-cell lung cancer (SCLC).
Targeting these proteins with navitoclax (formerly ABT263, a dual BCL-xL/2 inhibitor) …

Bcl-xL is a well-characterized target gene of cancer. DT2216, a selective proteolysis-
targeting chimera (PROTAC) has been developed for targeting Bcl-xL without causing …

Background Inhibition of antiapoptotic B‐cell lymphoma 2 (BCL2) proteins by small
molecule Bcl‐2 homology 3 (BH3) mimetics causes rapid induction of apoptosis of human …

Proteolysis‐targeting chimeras (PROTACs) is a targeted protein degradation (TPD)
technique effected by hijacking the ubiquitin‐proteasome system (UPS) of the cells. A …